Recursion is an AI-native biotech with its lead asset REC-4881 showing 53% polyp reduction at week 25 in the TUPELO trial (FAP prevention — a devastating genetic cancer condition). FDA registrational study design update expected September-October 2026 is the binary catalyst. Analyst avg target $8.10 implies +119% upside. New CEO Najat Khan (ex-Novartis) and CMO Vicki Goodman (ex-Pfizer) signal a pivot to clinical execution — but this is a binary, pre-revenue biotech with ~$81M/quarter cash burn.
📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม
ค่าขนม — ARK bought, analyst avg $8 (+119%). TUPELO 53% polyp reduction is a genuine medical breakthrough in an unmet need. Size very small (1–3%) and treat as binary option: FDA pathway confirmed = 2–3x; rejected = -50%+.
88
score / 100 ⓘ
⚡ Catalyst
🔬 REC-4881 FDA Registrational Study Design Update~90-120 DAYS
FDA meeting to confirm registrational pathway for REC-4881 in FAP (Familial Adenomatous Polyposis). TUPELO trial: 53% polyp reduction at wk 25 — unprecedented efficacy for a rare disease with no approved treatment. Sep-Oct 2026 timeline.
~Sep-Oct 2026
📊 Q2 2026 Earnings34 DAYS
Aug 4, 2026. Key watch: REC-4881 TUPELO trial update (wk 48 data), cash runway update, any new partnerships or licensing deals from AI platform.
Aug 4, 2026
🤖 AI Platform PartnershipsONGOING
Recursion's Recursion OS AI drug discovery platform has existing partnerships with Roche, Bayer, and NVIDIA. Additional enterprise licensing deals or co-development agreements would add non-dilutive capital.
H2 2026
🎯 Entry Point
Entry 1
$3.69
Current — speculative position post-ARK buy signal, pre-FDA updateNow (small)
Entry 2PREFERRED
$3.1–3.3
If macro selloff / biotech sector rotationOn any pullback
Entry 3
$2.50
Near 52-wk support — thesis unchanged; FDA pathway still intactDeep dip only
✅ Take Profit
TP1
Base — wk 48 TUPELO data positive / Q2 beat
$5
+35.5%
TP2
Bull — FDA confirms registrational pathway + partnership expansion
$7
+89.7%
TP3 🌙
Moon — analyst high target; NDA submission + M&A premium
$11
+198.1%
🔴 Stop Loss
Tight Stop
Below Mar 2026 support = clinical concerns emerging
$2.9
-21%
Hard Stop
FDA rejects registrational pathway or TUPELO wk 48 data disappoints
$2.1
-43%
Risk / Reward
Tight stop vs TP2
3.2 : 1
⚠ ค่าขนม — binary clinical play. Size ≤3% of portfolio.
📅 Estimate Date
Q2 2026 Earnings
TUPELO wk 48 data update + cash burn + partnerships — key read on clinical momentum
Aug 4, 2026
est. -$0.15 EPS (non-GAAP)
FDA REC-4881 Registrational Study Design
FDA meeting confirms registrational trial design — binary outcome for FAP indication
Sep-Oct 2026
Binary: go/no-go
📈 Stock Timeline
2 snapshots · Jun 30 → Jul 1
Score
▲ 10
52
Jun 30Jul 1
TP2 Target
$7
Jun 30Jul 1
Rank
▼ 2
#14
Jun 30Jul 1
📈 Possible Up % — Scenario Spread
Bear
-40%
$2
Base
+40%
$5
Bull
+100%
$7
Moon
+198%
$11
← downsideupside →
🏛️ Fed / Macro Risk — LOW
Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution
Rate Outlook
Fed at 3.50–3.75%; biotech valuations are driven by clinical data and FDA decisions, not rate cycles. RXRX is pre-revenue — rate moves don't directly affect pipeline value.
Inflation
Core PCE 3.4%; biotech clinical costs are inflation-exposed but RXRX has locked-in TUPELO trial costs. Cash burn is the primary financial risk, not inflation.
Sector Impact
Biotech M&A is accelerating — pharma giants (Roche, Bayer already partnered) are hunting AI drug discovery platforms. Clinical success = acquisition premium scenario.
Summary
LOW — biotech is rate-insensitive; value is binary on clinical data. Primary risk is clinical failure, not macro.
🎯 Analyst Targets
Wall Street price targets vs the current price — cross-check our TP levels
Consensus Avg (8 analysts)
Buy$8+117%
High Target
Strong Buy$11+198%
Low Target
Neutral$5+36%
current price $3.69
🔍 Similar-Catalyst Comparable Check
Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic
FOLD✅ GoodJun 2023
+54%
in 1 day
FDA orphan drug fast-track pathway confirmation for Fabry disease treatment
Amicus Therapeutics (FOLD) received FDA orphan drug pathway confirmation for a rare genetic disease with no prior treatment — directly comparable to REC-4881 in FAP. Stock +54% on the day. RXRX FAP indication is similarly orphan-eligible.
PTCT✅ GoodQ2 2024
+40%
in 2 days
FDA rare disease regulatory pathway confirmation for Duchenne muscular dystrophy
PTC Therapeutics rare disease pathway confirmation showed +40% move. Unmet medical need + orphan status = FDA collaboration mode. RXRX TUPELO 53% polyp reduction sets up similarly.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode
Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.
⚠️
Use this stop-loss set (-21% / -30%) only when trading the earnings spot — not for the core holding (use the -21% / -43% set above). If you are holding long-term, follow the core set.
📈Pre-Catalyst Run-up Pattern
+20–40%Now → Sep 2026
Biotech FDA feedback events typically see 20-40% pre-run in the 2-4 weeks before if trial data is strong. RXRX TUPELO 53% wk-25 data = strong foundation for pre-run. Sep-Oct FDA meeting = accumulation window now through August.
🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +60%
range: +40% to +100%· FOLD Jun 2023
Biotech small-cap FDA pathway confirmations in rare disease: avg +60-100% on the day. FAP is a rare (1/8,000) disease with no approved treatment — orphan drug designation = fast-track potential. Examples: FOLD (FDA pathway confirm 2023: +54%), PTCT (rare disease pathway confirm 2024: +40%).
❌ Catalyst Missavg -45%
range: -35% to -60%· ACAD 2022 (FDA refusal -50%)
FDA rejection of novel rare disease pathway in small biotech = -40 to -60% crash. RXRX at $3.69 = limited absolute downside but still -$1.50 per share worst case.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio
Binary FDA outcome; no approved treatment precedent for FAP chemopreventive. Analyst upside +119% is high but pure binary. ≤2-3% of portfolio maximum — ค่าขนม sizing.
🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-21%($2.9)
Below Mar support = TUPELO wk 48 data concerns or trial modification
After Catalyst (Bad Result)-30%
If FDA declines to meet / issues a CRL = exit immediately; do not average down on regulatory rejection